Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The pathological implication of amyloid precursor protein (APP) in Alzheimer's disease has been widely documented due to its involvement in the generation of amyloid-β peptide. However, the physiological functions of APP are still poorly understood. APP is considered a multimodal protein due to its role in a wide variety of processes, both in the embryo and in the adult brain. Specifically, APP seems to play a key role in the proliferation, differentiation and maturation of neural stem cells. In addition, APP can be processed through two canonical processing pathways, generating different functionally active fragments: soluble APP-α, soluble APP-β, amyloid-β peptide and the APP intracellular C-terminal domain. These fragments also appear to modulate various functions in neural stem cells, including the processes of proliferation, neurogenesis, gliogenesis or cell death. However, the molecular mechanisms involved in these effects are still unclear. In this review, we summarize the physiological functions of APP and its main proteolytic derivatives in neural stem cells, as well as the possible signaling pathways that could be implicated in these effects. The knowledge of these functions and signaling pathways involved in the onset or during the development of Alzheimer's disease is essential to advance the understanding of the pathogenesis of Alzheimer's disease, and in the search for potential therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965 · cited 4×
“Processing of the C99 fragment by γ-secretase at multiple sites generate cleavage fragments of 43, 45, 46, 48, 49 and 51 amino acids, which are further cleaved to the main Aβ isoforms, Aβ40 and Aβ42 (Aβ peptides of 40 and 42 amino acids, respectively) (Chen et al., 2017).”
BackgroundInfluentialA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“In addition, as discussed above, mutations in the APP gene (with the exception of A673T mutation) (Jonsson et al., 2012) are associated with the appearance of familial AD, since they all favor the production of Aβ peptide (Van Dam and De Deyn, 2006).”
BackgroundAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“Mutations in the APP gene are associated with the appearance of familial AD, which represents 5% of AD cases and is characterized by its early onset (before 65 years of age) (Karch and Goate, 2015).”
BackgroundTrafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 2×
“Next, the γ-secretase enzymatic complex cleaves the C83 fragment, releasing the soluble peptide p3 to the extracellular medium and the AICD fragment to the cytoplasm (Haass et al., 2012; Grimm et al., 2013).”
BackgroundNot just amyloid: physiological functions of the amyloid precursor protein family
Müller, U. C., Deller, T., & Korte, M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.29 · Cited by 634 · cited 3×
“The studies carried out during recent years have established APP as a multimodal protein that can modulate a variety of biological processes, ranging from transcriptional regulation to synaptic functions (Müller et al., 2017).”
BackgroundTraumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?
Johnson, V. E., Stewart, W., & Smith, D. H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2808 · Cited by 587 · cited 1×
“The formation of these plaques in the brain is the main histopathological feature of Alzheimer’s disease (AD) (Gouras et al., 2015), although they also appear in other neurological conditions such as Down syndrome (Lee et al., 2017) or traumatic brain injury (Johnson et al., 2010).”
BackgroundAβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
η-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398 · cited 1×
“The η-secretase pathway (Willem et al., 2015), the δ-secretase pathway (Zhang et al., 2015) and the meprin pathway (Jefferson et al., 2011) have been discovered in which additional N-terminal derivatives of APP are generated.”
BackgroundOchalek, A., Mihalik, B., Avci, H. X., Chandrasekaran, A., Téglási, A., Bock, I., Giudice, M. L., Táncos, Z., Molnár, K., László, L., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0317-z · Cited by 225
Morel, E., Chamoun, Z., Lasiecka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., Dall’Armi, C., Simoes, S., Point Du Jour, K. S., McCabe, B. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3250 · Cited by 222 · cited 1×
“Several authors have proposed that the amyloidogenic pathway takes place in endosomes and this hypothesis is increasingly accepted (Morel et al., 2013).”
Background
Cited by
Neuroinflammation and neurogenesis in Alzheimer's disease and potential therapeutic approaches
Sung, P.-S., Lin, P.-Y., Liu, C.-H., Su, H.-C., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030701 · Cited by 193
Dysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies
Kurz, C., Walker, L., Rauchmann, B., & Perneczky, R. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12782 · Cited by 183
“Depending on the splicing site of secretases, an “amyloidogenic”—“Aβ”—pathway leading to insoluble amyloid peptides and a “non-amyloidogenic”—“non-Aβ”—pathway leading to soluble amyloid peptides exist.(1,21) Splicing by β-secretases produces Aβ peptides ranging from 39 to 43 amino acids(21,22) DYSFUNCTION OF THE BLOOD…”
BackgroundBukke, V. N., Archana, M., Villani, R., Romano, A. D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., & Cassano, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207452 · Cited by 161
Metadata
- Authors
- Liste, I., Coronel, R., Palmer, C., Bernabeu-Zornoza, A., Monteagudo, M., Rosca, A., & Zambrano, A.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2019
- Volume
- 14
- Issue
- 10
- Pages
- 1661
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W2947263120
- Cited by
- 42
- References
- 19
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.